Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tehran Heart Center | OTHER |
Not provided
Not provided
Not provided
This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication. The goal of present study is to investigate if periprocedural administration of 10 mg once daily empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2I), can reduce the incidence of post-operative atrial fibrillation and/or atrial flutter in patients with chronic coronary syndrome scheduled for isolated CABG. This trial will be conducted in two referral teaching cardiology hospitals in Tehran. 492 adult patients who are scheduled for elective isolated coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of intervention (empagliflozin 10 mg daily) or placebo starting 3 days before surgery until discharge.
Study aim: Evaluating the role of empagliflozin on the rate of postoperative atrial fibrillation in comparison with placebo Design: Two arms, parallel-group, phase 3, randomized, double-blind, placebo-controlled trial on 492 patients Settings and conduct: Recruitment site: Tehran Heart Center and Rajaie Cardiovascular Medical and Research Center For blinding, the drug or placebo will be given to the ward based on the patient's code in the randomization system For monitoring, the blood samples for creatinine, sodium, potassium, and fasting blood sugar along with clinical evaluations will be given on day 0 and daily thereafter (max= 30 days) in specific wards and will be compared at the end of any atrial fibrillation lasting longer than 30 seconds based on 24-hour 12-lead ECG monitoring will be accepted as atrial fibrillation After entering the study, the patients are placed in one of two groups, sample and control; in the sample group, they are treated with the usual treatment regimen plus empagliflozin at a dose of 10 mg during the hospitalization period. Patients in the control arm will receive a matching placebo.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital. |
|
| Comperator | Placebo Comparator | The comparator group will receive a matching placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Empagliflozin 10 MG | Drug | The intervention group will receive a 10 mg tablet of empagliflozin once a day from 3 days before surgery until discharge from the hospital. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of POAF | Incidence of new-onset postoperative atrial fibrillation (AF) and/or atrial flutter (AFL), defined as any adjudicated documented AF or AFL of at least 30 seconds duration and documented by Holter ECG monitoring during the admission time in the ICU (at least 72 hours and maximum 30 days). | From CABG until discharge from the intensive care unit (at least 72 hours and maximum 30 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Composite Incidence of all arrhythmias leading to hemodynamic instability | Defined as any adjudicated documented tachy- or bradyarrhythmia of at least 30 seconds duration and documented by rhythm strips or 12-lead ECG leading to hemodynamic instability during the admission time. Ventricular tachycardia (VT) of at least 30 seconds duration and documented by rhythm strip or 12-lead ECG. Ventricular fibrillation (VF) of at least 30 seconds duration and documented by rhythm strip or 12-lead ECG |
Not provided
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hessam Kakavand, PharmD | Contact | +982144605351 | hessamkakavand@yahoo.com | |
| Maryam Aghakouchakzadeh, PharmD | Contact | +982188029600 | m.aghakouchakzadeh@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tehran Heart Center | Recruiting | Tehran | 1411713138 | Iran |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| C570240 | empagliflozin |
Not provided
Not provided
Not provided
Two arms, parallel-group, phase 3, randomized, double-blind, placebo-controlled trial with allocation sequence concealment and blinded endpoint adjudication on 492 patients
Not provided
Not provided
Neither the participants nor the researchers know which treatment or intervention patients are receiving
| Placebo | Drug | The comparator group will receive a matching placebo from 3 days before surgery until discharge from the hospital. |
|
| From CABG until discharge from the hospital (maximum 30 days). |
| Incidence of post-operative acute kidney injury | Defined as the presence of either the increase in serum creatinine by ≥ 0.3 mg/dl (≥ 26.5 µmol/l) within 48 hours; or an increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume < 0.5 ml/kg/h for 6 hours based on the KDIGO definition of AKI | From CABG until 7th post-operation day. |
| Need for vasopressor/inotrope | Defined as cumulative vasopressor index and the amount of average daily inotrope dose during the admission time in the ICU | From CABG until discharge from the intensive care unit (maximum 30 days). |
| Duration of hospitalization | Defined as number of days a patient stay at the hospital | From CABG until discharge from the hospital. |
| All-cause mortality | Defined as adjudicated 30-day mortality, including cause-specific mortality: cardiac arrhythmic, cardiac non-arrhythmic, and non-cardiovascular. | From CABG until 30th post-operation day. |
| Incidence of life-threatening infections | Defined as any adjudicated laboratory and clinically confirmed systemic infection that necessitate the administration of parenteral broad spectrum antibiotics | From CABG until discharge (maximum 30 days). |
| Incidence of genitourinary tract infections | Defined as any adjudicated laboratory and clinically confirmed genitourinary tract infection including cystitis, pyelonephritis, prostatitis, urethritis, and vaginitis | From CABG until discharge from the hospital (maximum 30 days). |
| Incidence of hypoglycemia | Defined as serum blood sugar ≤ 70 mg/dL (≤ 3.9 mmol/L) | From CABG until discharge from the hospital (maximum 30 days). |
| Incidence of ketoacidosis | Defined as blood pH ≤ 7.3, serum bicarbonate less than 15 mEq/l, and presence of ketonemia or ketonuria | From CABG until discharge from the hospital (maximum 30 days). |
| Incidence of clinically-diagnosed ischemic stroke | Defined as the sudden loss of blood circulation to an area of the brain that has been confirmed with appropriate diagnostic imaging (Brain CT/MRI) | From CABG until 30th post-operation day. |
| Composite incidence of arterial and venous thrombosis | Defined as adjudicated arterial thrombosis (including Type I MI and peripheral arterial thrombosis) and venous thrombosis (including DVT and PE) confirmed with appropriate diagnostic tools | From CABG until 30th post-operation day. |
| Need for renal replacement therapy | defined as treatment with any forms of dialysis (hemodialysis, hemodiafiltration, and peritoneal dialysis), hemofiltration, and renal transplantation | From CABG until discharge from the intensive care unit (maximum 30 days). |
| Rajaie Cardiovascular Medical & Research Center | Recruiting | Tehran | 1995614331 | Iran |
|
| D013568 |
| Pathological Conditions, Signs and Symptoms |